Solid Biosciences Q2 net loss widens to $39.5 mln
Overview
Solid Biosciences reports Q2 2025 net loss of $39.5 mln, up from Q2 2024
R&D expenses rose due to increased costs for SGT-003 program
Company ended Q2 2025 with $268.1 mln in cash, runway into H1 2027
Outlook
Company to discuss SGT-003 regulatory pathways with FDA in Q4 2025
Company expects SGT-212 Phase 1b trial initiation in Q4 2025
SGT-501 Phase 1b trial initiation expected in Q4 2025
Solid anticipates cash runway into H1 2027
Result Drivers
INCREASED R&D EXPENSES - R&D expenses rose due to manufacturing, regulatory, and clinical costs for SGT-003
CASH POSITION - Company ended Q2 with $268.1 mln in cash
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS | -$0.42 | ||
Q2 Net Income | -$39.50 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 62% above its August 11 closing price of $6.08
Press Release:
